
Opinion|Videos|April 28, 2025
FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
Author(s)Nihar Desai, MD, MPH
Nathan Wong, PhD
Nathan Wong, PhD
Experts discuss FDA-approved therapies for high lipoprotein(a) [Lp[a]) levels, their benefits and shortcomings, the frequency of their use in health plans, emerging therapies in the pipeline, and the expected timeline for associated data release.
Advertisement
Video content above is prompted by the following:
- What therapies for high Lp(a) levels are currently approved by the FDA?
- What benefits and shortcomings (eg, cost, time) are associated with this therapy?
- How frequently is this therapy used in the health plans you work with?
- What therapies are in the pipeline?
- When do we expect associated data to be released?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
3
Supporting Pharmacy Residents in Completing Research Projects at UC Davis: Jeremiah J. Duby, PharmD, BCPS, BCCCP
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5